Advertisement
News
Subscribe to MDT Magazine News

Detailed Cholesterol Test Provides Vital Clues for Women in Search of PCOS Answers

September 9, 2010 10:32 am | by Bio-Medicine.Org | Comments

BIRMINGHAM, Ala., Sept. 9 /- Polycystic Ovarian Syndrome, known as PCOS, is a silent and often mysterious disease that plays havoc with a woman's body and increases the risk of serious illness. PCOS is the number one cause of female infertility and increases the risk of heart disease,...

TOPICS:

Luminex Corporation to Present at UBS Global Life Sciences Conference

September 9, 2010 10:31 am | by Bio-Medicine.Org | Comments

AUSTIN, Texas, Sept. 9 /- Luminex Corporation (Nasdaq: LMNX ) today announced that management will present at UBS Global Life Sciences Conference to be held September 20 - 22, 2010, in New York City, New York. (Logo:   http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) (Logo:...

TOPICS:

Newcastle University and ISAEC to research genetics of drug induced liver injury

September 9, 2010 8:35 am | by EurekAlert | Comments

(Edelman Public Relations) The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with Newcastle University to research the genetics of drug induced liver injury. The SAEC is a novel, non-profit international research consortium, formed by...

TOPICS:
Advertisement

University of Liverpool and ISAEC to research genetics of drug-induced hypersensitivity reactions

September 9, 2010 8:35 am | by EurekAlert | Comments

(Edelman Public Relations) The International Serious Adverse Events Consortium (SAEC) announced today it will collaborate with The University of Liverpool to research the genetics of a form of serious adverse drug reaction called hypersensitivity. These are thought to involve the...

TOPICS:

Aging drug users are increasing and facing chronic physical and mental health problems

September 9, 2010 8:35 am | by EurekAlert | Comments

(Wiley-Blackwell) Health and social services are facing a new challenge, as many illicit drug users get older and face chronic health problems and a reduced quality of life. Researchers interviewed people aged 49-61 in contact with voluntary sector drug treatment services. The...

TOPICS:

Anchor Therapeutics licensing deal to net up to $480M

September 9, 2010 8:34 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge biotech Anchor Therapeutics Inc. stands to receive up to $480 million from New Jersey-based Ortho-McNeil Janssen Pharmaceuticals Inc., related to a collaborative research and licensing deal associated with Anchor’s pepducin technology.

New Study: Physician Adoption of Live Video Detailing Has Doubled Since 2008, But Will Likely Plateau Until 2012 as Pharma Optimizes Targeting

September 9, 2010 8:34 am | by Bio-Medicine.Org | Comments

NEW YORK, Sept. 9 /- Live video detailing has made a strong comeback after a false start in the early 2000s, according to pharmaceutical and healthcare market research company Manhattan Research's ePharma Physician ® v10.0 study. Physician adoption of live video detailing has more...

TOPICS:

Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection

September 9, 2010 8:34 am | by Bio-Medicine.Org | Comments

SAN FRANCISCO, Sept. 9 /- Medizone International, Inc. (OTC Bulletin Board, OTCQB: MZEI) announces it has filed an additional international patent application covering recent developments in its variant of AsepticSure™ designed for government use in bio-terrorism countermeasures....

TOPICS:
Advertisement

Misonix Announces New Distribution Agreement For Spain

September 9, 2010 8:33 am | by Bio-Medicine.Org | Comments

FARMINGDALE, N.Y., Sept. 9 /- Misonix, Inc. (Nasdaq: MSON ), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has entered into a new, three year, exclusive distribution agreement with Dismeval, s.l.,  based in...

TOPICS:

Acceleron signs lucrative development deal with Shire

September 9, 2010 8:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Acceleron Pharma Inc. and Shire plc have signed a development and commercialization deal associated with Acceleron’s novel molecules linked to skeletal muscle growth. The agreement will bring in $45 million in upfront payments to Acceleron, along with additional payments of up to $453 million.

TOPICS:

Survey Reveals Roughly 3 in 5 Women May be Mistreating Their Yeast Infections

September 9, 2010 8:33 am | by Bio-Medicine.Org | Comments

SKILLMAN, N.J., Sept. 9 /- For more information, please go to: http://monistat.presslift.com/yeastinfections . Few women go through life having never suffered from the uncomfortable symptoms of a yeast infection.  In fact, nearly 3 in 4 (72 percent) women will experience their first...

TOPICS:

Dr. Robert Shorr, Leading Scientist in Cancer Metabolism, to Speak at Two Upcoming Pharmaceutical Conferences

September 9, 2010 8:33 am | by Bio-Medicine.Org | Comments

CRANBURY, N.J., Sept. 9 /- Cornerstone Pharmaceuticals, Inc., the cancer metabolism company, today announced that its CEO, Robert Shorr, Ph.D., D.I.C., will be speaking and Co-Chairing The Center for Business Intelligence's (CBI's) 4th Annual Oncology Clinical Trials Summit and chairing a...

TOPICS:

Joint replacement: Does this look infected to you?

September 9, 2010 8:32 am | by EurekAlert | Comments

(American Academy of Orthopaedic Surgeons) Clinical practice guidelines are one avenue the AAOS uses to ensure that patients receive high quality care. A periprosthetic joint infection occurs when bacteria or other foreign organisms enter the wound during or at any point following joint...

TOPICS:

2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort

September 9, 2010 8:32 am | by Bio-Medicine.Org | Comments

NEW YORK, Sept. 9 /- The Prix Galien USA committee, responsible for awarding the most prestigious prize in biopharmaceutical research and development, today announced the 2010 winner of the Pro Bono Humanum Award for the 4th annual Prix Galien USA Awards competition. The award,...

TOPICS:

Halozyme prices sale of 8.3M shares at $7.50 each

September 9, 2010 6:45 am | by The Associated Press | Comments

Halozyme Therapeutics Inc. said Thursday it priced an offering of 8.3 million shares of its stock at $7.50 per share.The underwriters of the offering will have an option to buy another 1.2 million shares to cover any overallotments.Shares of Halozyme closed at $7.99 Wednesday, making the price...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading